129.70
price down icon0.77%   -1.01
pre-market  プレマーケット:  129.70  
loading
前日終値:
$130.71
開ける:
$130.62
24時間の取引高:
889.91K
Relative Volume:
0.80
時価総額:
$13.02B
収益:
$2.86B
当期純損益:
$478.60M
株価収益率:
27.79
EPS:
4.6676
ネットキャッシュフロー:
$748.70M
1週間 パフォーマンス:
+1.50%
1か月 パフォーマンス:
-0.31%
6か月 パフォーマンス:
-10.69%
1年 パフォーマンス:
+17.58%
1日の値動き範囲:
Value
$127.07
$132.25
1週間の範囲:
Value
$127.07
$132.25
52週間の値動き範囲:
Value
$84.23
$160.18

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1114)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
2,000
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
129.70 13.02B 2.86B 478.60M 748.70M 4.6676
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
18.11 57.21B 29.85B 776.90M 4.35B 0.2408
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
115.99 48.96B 9.47B 2.67B 2.28B 6.0218
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.23 45.55B 14.54B 2.22B 2.58B 0.4871
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
29.44 34.29B 17.41B 1.43B 1.00B 1.2182
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
527.00 23.10B 3.18B 1.33B 1.04B 27.90

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-02-24 開始されました Wolfe Research Outperform
2026-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-10-21 開始されました Citigroup Buy
2025-07-21 開始されました Truist Buy
2025-07-10 開始されました Goldman Buy
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
Mar 18, 2026

Wolfe Research initiates coverage of Neurocrine Biosciences (NBIX) with outperform recommendation - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

Truist lowers Neurocrine Biosciences, Inc.’s (NBIX) PT following 2026 outlook update - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

Neurocrine Biosciences promotes Andrew Ratz to operations chief By Investing.com - Investing.com South Africa

Mar 18, 2026
pulisher
Mar 17, 2026

Neurocrine at Stifel CNS Forum: Growth and Strategic Focus - Investing.com

Mar 17, 2026
pulisher
Mar 17, 2026

Transcript : Neurocrine Biosciences, Inc. Presents at Stifel 2026 Virtual CNS Forum, Mar-17-2026 04 - marketscreener.com

Mar 17, 2026
pulisher
Mar 17, 2026

Neurocrine Biosciences (NBIX) CTO Ratz reports initial stock and option grants - Stock Titan

Mar 17, 2026
pulisher
Mar 17, 2026

Neurocrine Biosciences promotes Andrew Ratz to operations chief - Investing.com

Mar 17, 2026
pulisher
Mar 17, 2026

Neurocrine Biosciences promotes Andrew Ratz to chief technical operations officer - StreetInsider

Mar 17, 2026
pulisher
Mar 17, 2026

Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer - PR Newswire

Mar 17, 2026
pulisher
Mar 17, 2026

Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating - MSN

Mar 17, 2026
pulisher
Mar 16, 2026

Neurocrine Biosciences: The Song Remains The Same (NASDAQ:NBIX) - Seeking Alpha

Mar 16, 2026
pulisher
Mar 16, 2026

Iron Triangle Partners LP Acquires New Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 16, 2026
pulisher
Mar 16, 2026

Distillate Capital Partners LLC Trims Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 16, 2026
pulisher
Mar 16, 2026

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Mar 16, 2026
pulisher
Mar 15, 2026

Boone Capital Management Decreases Stake in Neurocrine Biosciences - National Today

Mar 15, 2026
pulisher
Mar 15, 2026

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Braidwell LP - MarketBeat

Mar 15, 2026
pulisher
Mar 15, 2026

Boone Capital Management LLC Has $23.36 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 15, 2026
pulisher
Mar 15, 2026

Assessing Neurocrine Biosciences (NBIX) Valuation After GARP Recognition And Reaffirmed Confidence In Ingrezza - simplywall.st

Mar 15, 2026
pulisher
Mar 14, 2026

Dodge & Cox Decreases Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 14, 2026
pulisher
Mar 14, 2026

2Xideas AG Trims Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 14, 2026
pulisher
Mar 13, 2026

Swiss National Bank Sells 14,100 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 13, 2026
pulisher
Mar 13, 2026

Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top GARP Pick with Strong Growth and a Reasonable Price - ChartMill

Mar 13, 2026
pulisher
Mar 13, 2026

Connor Clark & Lunn Investment Management Ltd. Acquires 32,480 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 13, 2026
pulisher
Mar 12, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

Neurology stocks rebound in 2025 after midyear slump - bioworld.com

Mar 12, 2026
pulisher
Mar 12, 2026

Magnetar Financial LLC Acquires New Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

Korea Investment CORP Has $10.06 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

First Trust Advisors LP Has $50.97 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 12, 2026
pulisher
Mar 12, 2026

Capital Fund Management S.A. Has $17.37 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 12, 2026
pulisher
Mar 11, 2026

Is It Time To Reassess Neurocrine Biosciences (NBIX) After The Recent Share Price Pullback - simplywall.st

Mar 11, 2026
pulisher
Mar 11, 2026

A Look At Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Pullback - Yahoo Finance

Mar 11, 2026
pulisher
Mar 11, 2026

Victory Capital Management Inc. Buys 31,981 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 11, 2026
pulisher
Mar 11, 2026

Cantor Fitzgerald Keeps Overweight on NBIX Neurocrine Biosciences March 2026 - Meyka

Mar 11, 2026
pulisher
Mar 10, 2026

Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum - PR Newswire

Mar 10, 2026
pulisher
Mar 10, 2026

Cantor Fitzgerald raises Neurocrine Bio price target on Ingrezza outlook By Investing.com - Investing.com Canada

Mar 10, 2026
pulisher
Mar 10, 2026

Barclays Increases Stake in Neurocrine Biosciences - National Today

Mar 10, 2026
pulisher
Mar 10, 2026

Neurocrine Biosciences, Inc. $NBIX Shares Bought by Barclays PLC - MarketBeat

Mar 10, 2026
pulisher
Mar 10, 2026

American Century Companies Inc. Sells 52,349 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 10, 2026
pulisher
Mar 09, 2026

Transcript : Neurocrine Biosciences, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08 - marketscreener.com

Mar 09, 2026
pulisher
Mar 09, 2026

The Technical Signals Behind (NBIX) That Institutions Follow - Stock Traders Daily

Mar 09, 2026
pulisher
Mar 08, 2026

Rhenman & Partners Asset Management Trims Neurocrine Biosciences Stake - National Today

Mar 08, 2026
pulisher
Mar 08, 2026

Rhenman & Partners Asset Management AB Sells 34,500 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 08, 2026
pulisher
Mar 08, 2026

14,653 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Munich Reinsurance Co Stock Corp in Munich - MarketBeat

Mar 08, 2026
pulisher
Mar 07, 2026

What insider trading reveals about Neurocrine Biosciences Inc. stockM&A Rumor & Reliable Entry Point Alerts - Naître et grandir

Mar 07, 2026
pulisher
Mar 06, 2026

Equifax Expands Data Solutions While Neurocrine Biosciences Advances Neurological Treatment Research - geneonline.com

Mar 06, 2026
pulisher
Mar 06, 2026

Two stocks flagged for study: Equifax and Neurocrine Bio review - Stock Titan

Mar 06, 2026
pulisher
Mar 06, 2026

Focus Partners Advisor Solutions LLC Buys 8,011 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Mar 06, 2026
pulisher
Mar 05, 2026

Neurocrine Biosciences (NBIX) CFO discloses bona fide gift of shares - Stock Titan

Mar 05, 2026
pulisher
Mar 05, 2026

Neurocrine Biosciences, Inc. $NBIX Shares Sold by Teachers Retirement System of The State of Kentucky - MarketBeat

Mar 05, 2026
pulisher
Mar 05, 2026

GW&K Investment Management Trims Neurocrine Biosciences Stake - National Today

Mar 05, 2026

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_specialty_generic RGC
$27.01
price up icon 2.39%
$25.12
price up icon 1.17%
drug_manufacturers_specialty_generic RDY
$14.14
price up icon 2.02%
$13.50
price down icon 1.75%
$527.00
price down icon 0.63%
大文字化:     |  ボリューム (24 時間):